Search

Your search keyword '"Stephenson, Tara"' showing total 35 results
Start Over Author "Stephenson, Tara" Language english
35 results on '"Stephenson, Tara"'

1. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Author

Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad Z., Bahlis, Nizar J., van de Donk, Niels W. C. J., and Verona, Raluca I.

Published
2024
Full Text
View/download PDF

2. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Author

Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, and Girgis, Suzette

Published
2023
Full Text
View/download PDF

3. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Author

Frerichs, Kristine A., Verkleij, Christie P. M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, van der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., and van de Donk, Niels W. C. J.

Published
2024
Full Text
View/download PDF

5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Author

Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita

Published
2021
Full Text
View/download PDF

8. Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels WCJ, Garfall, Alfred L, Benboubker, Lotfi, Uttervall, Katarina, Groen, Kaz, Rosiñol, Laura, Matous, Jeffrey V, Vishwamitra, Deeksha, Hodin, Caroline, Stephenson, Tara, Qi, Keqin, Zuppa, Athena, Chastain, Katherine, and Mateos, María-Victoria

Published
2024
Full Text
View/download PDF

9. MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels WCJ, Garfall, Alfred L, Benboubker, Lotfi, Uttervall, Katarina, Groen, Kaz, Rosiñol, Laura, Matous, Jeffrey V, Vishwamitra, Deeksha, Hodin, Caroline, Stephenson, Tara, Qi, Keqin, Zuppa, Athena, Chastain, Katherine, and Mateos, María-Victoria

Published
2024
Full Text
View/download PDF

10. MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Garfall, Alfred L, Nooka, Ajay K, van de Donk, Niels WCJ, Moreau, Philippe, Bhutani, Manisha, Oriol, Albert, G, Thomas, Rosiñol, Laura, Mateos, María-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquin, Y Krishnan, Amrita, Delforge, Michel, Huang, Lin, Vishwamitra, Deeksha, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2024
Full Text
View/download PDF

11. Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Garfall, Alfred L, Nooka, Ajay K, WCJ van de Donk, Niels, Moreau, Philippe, Bhutani, Manisha, Oriol, Albert, Martin, Thomas G, Rosiñol, Laura, Mateos, María-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquin, Krishnan, Amrita Y, Delforge, Michel, Huang, Lin, Vishwamitra, Deeksha, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2024
Full Text
View/download PDF

12. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Cortes-Selva, Diana, Casneuf, Tineke, Vishwamitra, Deeksha, Stein, Sarah, Perova, Tatiana, Skerget, Sheri, Ramos, Elena, van Steenbergen, Laure, De Maeyer, Dries, Boominathan, Rengasamy, Lau, Onsay, Davis, Cuc, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa M., Kobos, Rachel, Goldberg, Jenna D., Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad, Bahlis, Nizar Jacques, Van De Donk, Niels WCJ, and Verona, Raluca

Published
2022
Full Text
View/download PDF

13. An Exercise for Teaching the Employment Law Implications of Employee Blogging

Author

Lee, Konrad S., Thue, Matthew I., Oldham, Jar, and Stephenson, Tara N.

Abstract

This article provides a tool to help instructors introduce students to the intersection of blogging and employment law. Section II provides source materials on the subject. Specifically, it presents a summary overview of: (1) the development of blogging and other forms of online user generated content; (2) the legality of terminating an at-will employee for maintaining a blog; (3) the legality of terminating an employee for posting critical or confidential information on the Internet in violation of the employee duty of loyalty; and (4) constitutional considerations which limit an employer's ability to prosecute employee-bloggers who blog anonymously. Section III provides a hypothetical case study involving a fictional blogging employee who is terminated for publishing anti-employer information on the Internet. This case study, as well as the blog referenced in the case, is available to instructors and students through an actively maintained blog: http://darnoksucks.blogspot.com. Finally, Section IV contains questions and teaching notes related to the case study. The questions are also linked to the Danoksucks blog for easy student access. The teaching notes are meant for instructors only and are not available online. (Contains 115 footnotes.)

Published
2009
Full Text
View/download PDF

15. MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels, Moreau, Philippe, Garfall, Alfred, Bhutani, Manisha, Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Lopez, Joaquin Martinez, Krishnan, Amrita, Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2023
Full Text
View/download PDF

16. POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels, Moreau, Philippe, Garfall, Alfred, Bhutani, Manisha, Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Lopez, Joaquin Martinez, Krishnan, Amrita, Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2023
Full Text
View/download PDF

18. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Author

Miao, Xin, Wu, Liviawati S., Wang Lin, Shun Xin, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Verona, Raluca, Pei, Lixia, Su, Yaming, Ouellet, Daniele, Garfall, Alfred L., Krishnan, Amrita Y., Usmani, Saad, Girgis, Suzette, and Zhou, Honghui

Published
2022
Full Text
View/download PDF

20. The executive compensation dilemma: what should the board and compensation committee be doing?

Author

Storero, Jane K. and Stephenson, Tara

Subjects
Executives -- Compensation and benefits, Stock options, Labor contracts, Publicly held corporations, Compensation management, Financial disclosure, Disclosure (Securities law), Business, Human resources and labor relations, Insurance, Emergency Economic Stabilization Act of 2008
Abstract

Following the highly publicized Disney shareholder lawsuit where shareholders sued The Walt Disney Company board of directors, alleging violations of fiduciary duties based on the employment agreement entered into with [...]

Published
2009

21. P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS.

Author

Frerichs, Kristine, Verkleij, Christie, Mateos, Maria‐Victoria, Zweegman, Sonja, Groen, Kaz, Kuipers, Ilse, Martin, Tom, Rodriguez, Cesar, Nooka, Ajay, Kruijswijk, Sandy, Skerget, Sheri, Doyle, Margaret, Banerjee, Arnob, Chastain, Katherine, Perales‐Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Verona, Raluca, and van de Donk, Niels W.C.J.

Published
2023
Full Text
View/download PDF

23. Reducing compensation expense: valuing options in light of SFAS No. 123R

Author

Bowers, Helen, Stephenson, Tara, and Storero, Jane

Subjects
Stock price indexes -- Reports, Workers -- Compensation and benefits, Business, Human resources and labor relations, Insurance
Abstract

In 2004, the Financial Accounting Standards Board issued the Statement of Financial Accounting Standards (SFAS) No. 123, Share-Based Payment (SFAS 123R), which requires companies to report the value of unvested [...]

Published
2006

25. P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1.

Author

van de Donk, Niels W.C.J., Garfall, Alfred, Benboubker, Lotfi, Uttervall, Katarina, Groen, Kaz, Rosiñol Dachs, Laura, Hodin, Caroline, Stephenson, Tara, Trancucci, Danielle, Perales-Puchalt, Alfredo, Kobos, Rachel, Banerjee, Arnob, and Mateos, Maria-Victoria

Published
2023
Full Text
View/download PDF

26. P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

Author

Sidana, Surbhi, Moreau, Philippe, Garfall, Alfred, Bhutani, Manisha, Oriol, Albert, Nooka, Ajay, Martin, Tom, Rosiñol Dachs, Laura, Mateos, Maria-Victoria, Bahlis, Nizar J, Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquín, Krishnan, Amrita, Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and van de Donk, Niels W.C.J.

Published
2023
Full Text
View/download PDF

29. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Author

van de Donk, Niels W.C.J., Moreau, Philippe, Garfall, Alfred L., Bhutani, Manisha, Oriol, Albert, Nooka, Ajay K., Martin, Thomas G., Rosiñol, Laura, Mateos, Maria-Victoria, Bahlis, Nizar J., Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquin, Krishnan, Amrita Y., Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2023
Full Text
View/download PDF

30. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.

Author

Moreau, Philippe, van de Donk, Niels WCJ, Nahi, Hareth, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Popat, Rakesh, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Olyslager, Yunsi, Uhlar, Clarissa, Stephenson, Tara, and Rampelbergh, Rian Van

Abstract

This is a summary of a phase 1–2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. Most participants who took part in the study had at least 3 prior treatments for multiple myeloma before their cancer came back. A total of 165 participants from 9 countries were included in this study. All participants were given teclistamab once per week and monitored for side effects. Once participants started taking teclistamab, they were checked regularly to monitor if their cancer had no change, improved (responded to treatment), or worsened or spread (known as disease progression). After approximately 14.1 months of follow-up (from 2020 to 2021), 63% of participants who were given teclistamab had a decrease in myeloma burden, meaning that they responded to treatment with teclistamab. Participants who responded to teclistamab lived without their myeloma coming back for approximately 18.4 months. The most common side effects were infections, cytokine release syndrome, abnormally low white and red blood cell counts (neutropenia, lymphopenia, and anemia), and low platelet cell counts (thrombocytopenia). Approximately 65% of participants experienced serious side effects. Overall, more than half of the participants (63%) in the MajesTEC-1 study responded to treatment with teclistamab despite previous myeloma treatment failures. Clinical Trial Registration: NCT03145181, NCT04557098 (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Tara Stephenson

Author

Stephenson, Tara

Subjects
Feather Boy (Novel) -- Book reviews, Thursday's Child (Book), Remembrance (Book), Books -- Book reviews, Business, international, Publishing industry, Retail industry
Abstract

Waterstone's, York The most moving and thought-provoking novel for older readers that I have encountered for some time is Remembrance by Theresa Breslin. Set during the First World War and [...]

Published
2001

33. Nic Knight: Ottakar's, Milton Keynes. (Previews: February)

Author

Knight, Nic, Wood, Sheila, and Stephenson, Tara

Subjects
Love and Other Four Letter Words (Novel) -- Book reviews, Tuck Everlasting (Novel) -- Book reviews, Books -- Book reviews, Business, international, Publishing industry, Retail industry
Abstract

There are two completely different books that I really enjoyed this month. The first is Love and Other Four Letter Words (Walker, £4.99, 0744590086) by Carolyn Mackler. Sammie's mum is [...]

Published
2001

34. ACTIVE IN THE FIELD.

Author

Stephenson, Tara

Subjects
*JEWELRY, *ART metalwork, *HANDICRAFT, *AUCTIONS, *MUSEUM curators
Abstract

Deals with the issue of expanding the number of people interested in jewelry and metalsmithing. Presentation of contemporary American crafts at the Smithsonian Craft Show; Craft auction and dinner included in the Renwick Alliance Craft Weekend; Promotion by museum curators and gallery directors of jewelry and metalsmithing.

Published
2001

35. Teclistamab in Relapsed or Refractory Multiple Myeloma.

Author

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, and Usmani SZ

Subjects
Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Injections, Subcutaneous, Neoplasm Recurrence, Local drug therapy, Recurrence, T-Lymphocytes drug effects, T-Lymphocytes immunology, Antibodies, Bispecific administration & dosage, Antibodies, Bispecific adverse effects, Antibodies, Bispecific therapeutic use, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological therapeutic use, B-Cell Maturation Antigen antagonists & inhibitors, CD3 Complex antagonists & inhibitors, Multiple Myeloma drug therapy, Multiple Myeloma immunology, Multiple Myeloma pathology
Abstract

Background: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma., Methods: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better)., Results: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2)., Conclusions: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.)., (Copyright © 2022 Massachusetts Medical Society.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results